SNY Живые сигналы | Максимизируйте прибыль с Getagraph.com

Купить 343 min ago

@ $50.11

Выпущен: 8 май 2024 @ 17:41

Доходность: -0.02%

Предыдущий сигнал: май 6 - 19:16

Предыдущий сигнал: Продать

Доходность: 2.10 %

Live Chart Being Loaded With Signals

Commentary (8 май 2024 @ 23:00):
Our systems believe the stock currently is undervalued by 0.30% compare to its pairs and should correct upwards.

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally...

Stats
Объем за сегодня	1.60M
Средний объем	2.04M
Рыночная капитализация	118.18B
EPS	$0 ( 2024-04-25 )
Дата следующего отчета о доходах	( $0.890 ) 2024-07-26
Last Dividend	$1.903 ( 2023-05-30 )
Next Dividend	$0 ( N/A )
P/E	25.82
ATR14	$0.409 (0.82%)

Корреляция (AI algo v.1.1b): Undervalued: 0.30% $50.20 paired level. (Алгоритм отслеживает изменения наиболее коррелирующих акций в режиме реального времени и дает мгновенное обновление)

Объем Корреляция

Длинно: -0.80 (moderate negative)

Кратко: -0.33 (neutral)

Signal:(20) Neutral

Sanofi American Корреляция

10 Самые положительные корреляции
PPH	0.936
PWOD	0.93
ACAHU	0.925
WLFC	0.914
NWFL	0.914
EVOP	0.913
ROST	0.91
SGHT	0.909
HZNP	0.907
MGI	0.907

10 Самые отрицательные корреляции
LNSR	-0.936
MEDS	-0.922
VS	-0.919
RMRM	-0.916
LHDX	-0.915
STRC	-0.912
TIL	-0.911
ULBI	-0.91
QLGN	-0.91
PLMR	-0.909

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Sanofi American Корреляция - Валюта/Сырье

-0.36
( neutral )

0.04
( neutral )

0.00
( neutral )

0.19
( neutral )

0.12
( neutral )

-0.54
( weak negative )

Sanofi American Финансовые показатели

Annual	2023
Выручка:	$43.07B
Валовая прибыль:	$26.50B (61.52 %)
EPS:	$4.31

FY	2023
Выручка:	$43.07B
Валовая прибыль:	$26.50B (61.52 %)
EPS:	$4.31

FY	2022
Выручка:	$45.39B
Валовая прибыль:	$31.70B (69.83 %)
EPS:	$6.69

FY	2021
Выручка:	$39.18B
Валовая прибыль:	$26.92B (68.72 %)
EPS:	$2.49

Financial Reports:

No articles found.

Sanofi American Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$3.28 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Sanofi American Dividend Information - Dividend Knight

Dividend Sustainability Score: 3.13 - low (4.25%) | Divividend Growth Potential Score: 5.64 - Stable (12.84%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.462	2003-05-28
Last Dividend	$1.903	2023-05-30
Next Dividend	$0	N/A
Payout Date	2023-06-23
Next Payout Date	N/A
# dividends	24	--
Total Paid Out	$33.25	--
Avg. Dividend % Per Year	3.34%	--
Score	3.39	--
Div. Sustainability Score	3.13
Div.Growth Potential Score	5.64
Div. Directional Score	4.39	--

Next Divdend (Est)
(2025-02-10)

$1.985 Estimate 3.15 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.39

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	$0.462	1.49%
2004	$0.610	1.60%
2005	$0.799	2.01%
2006	$0.912	2.00%
2007	$1.145	2.48%
2008	$1.510	3.31%
2009	$1.419	4.34%
2010	$1.627	3.99%
2011	$1.822	5.55%
2012	$1.756	4.72%
2013	$1.862	3.89%
2014	$1.910	3.69%
2015	$1.618	3.55%
2016	$1.630	3.86%
2017	$1.577	3.84%
2018	$1.861	4.30%
2019	$1.739	4.06%
2020	$1.753	3.46%
2021	$1.906	3.91%
2022	$2.04	4.02%
2023	$3.28	6.69%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.123	1.500	7.54	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.0961	1.500	-0.0433	-0.0649	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	6.54	1.000	8.69	8.69	[3 - 30]
operatingCashFlowPerShareTTM	8.21	2.00	7.26	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.61	2.00	7.20	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.673	1.000	2.11	2.11	[0.2 - 0.8]
operatingProfitMarginTTM	0.212	1.000	7.76	7.76	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.13

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	16.25	1.000	8.46	0	[1 - 100]
returnOnEquityTTM	0.0961	2.50	-0.0278	-0.0649	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.61	2.00	8.13	10.00	[0 - 30]
dividendYielPercentageTTM	3.87	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	8.21	2.00	7.26	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.742	1.500	8.39	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.179	1.000	8.03	0	[0.1 - 0.5]
Total Score				5.64

Sanofi American

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.